Stay updated on Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Sign up to get notified when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.

Latest updates to the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedNew revision v3.3.2 was added and v3.3.1 was removed from the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision history shows a new revision v3.3.1 added and a prior revision v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedAdded a new 'Study Status' column in the Study History table and increased the version count to 24; removed the government funding lapse notice.SummaryDifference0.9%

- Check43 days agoChange DetectedNew 'Study Status' entry appears in the record history (dated 2025-10-29, version 23). An earlier entry dated 2025-09-25 was removed.SummaryDifference0.4%

- Check71 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference11%

- Check79 days agoChange DetectedUpdated revision history: added current date, updated study status, and bumped to v3.1.0; removed the older date and previous version v3.0.2.SummaryDifference1%

Stay in the know with updates to Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenalidomide and Daratumumab in High-Risk Smoldering Myeloma Clinical Trial page.